Literature DB >> 22371452

Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL.

Naoko Kanemitsu1, Yasushi Isobe, Azuchi Masuda, Shuji Momose, Morihiro Higashi, Jun-ichi Tamaru, Koichi Sugimoto, Norio Komatsu.   

Abstract

PURPOSE: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is closely associated with Epstein-Barr virus (EBV). To elucidate its pathogenetic role, we examined the expression profiles of EBV-encoded proteins, especially focusing on latent membrane protein 1 (LMP1). EXPERIMENTAL
DESIGN: Immunohistochemistry was carried out using clinical samples from ENKL cases, which were diagnosed between 1996 and 2010 at our institution. We statistically assessed the correlation between LMP1 positivity and the clinicopathologic data and further examined phosphorylation status of NF-κB RelA and Akt in ENKL cell lines.
RESULTS: Most of the 30 examined cases showed pleomorphic morphology, natural killer cell immunophenotype, and a localized disease. Immunohistochemistry detected EBERs, but not EBNA2, in all cases. LMP1 and LMP2A were positive in 22 (73.3%) and 12 cases (40.0%), respectively. LMP1-positive cases tended to show a localized disease (P = 0.060, the Fisher exact test). Nuclear localization of phosphorylated RelA and detection of phosphorylated Akt were predominantly observed in LMP1-positive cases (P = 0.002 and P < 0.001, respectively, the Fisher exact test). RNA silencing experiments of LMP1 in Hank1 cells suggested a positive correlation between LMP1 expression and phosphorylation of RelA and Akt. With a median follow-up period of 26.7 months (range, 0.2-142.3 months), the 2.5-year overall survival rates for LMP1-positive and -negative cases were estimated at 78.3% and 12.5%, respectively (P = 0.001, log-rank test).
CONCLUSIONS: LMP1 expression shows correlations with phosphorylation of RelA and Akt and possibly has a favorable impact on clinical outcome in ENKL. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371452     DOI: 10.1158/1078-0432.CCR-11-2395

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  EBV-related lymphomas: new approaches to treatment.

Authors:  Jennifer A Kanakry; Richard F Ambinder
Journal:  Curr Treat Options Oncol       Date:  2013-06

2.  Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior.

Authors:  Mineui Hong; Taehee Lee; So Young Kang; Suk-Jin Kim; Wonseog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

3.  Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

Authors:  N Nora Bennani; Aung M Tun; Kenneth R Carson; Jessica L Geiger; Lauren S Maeda; Kerry J Savage; Jim Rose; Lauren Pinter-Brown; Matthew A Lunning; Jeremy S Abramson; Nancy L Bartlett; Julie M Vose; Andrew M Evens; Sonali M Smith; Steven M Horwitz; Stephen M Ansell; Ranjana H Advani
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-10-16

Review 4.  Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

Authors:  Lindsay C George; Martin Rowe; Christopher P Fox
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 5.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

6.  BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.

Authors:  Nenad Sejic; Lindsay C George; Rosemary J Tierney; Catherine Chang; Olga Kondrashova; Ruth N MacKinnon; Ping Lan; Andrew I Bell; Guillaume Lessene; Heather M Long; Andreas Strasser; Claire Shannon-Lowe; Gemma L Kelly
Journal:  Blood Adv       Date:  2020-10-13

7.  Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.

Authors:  Motoko Yamaguchi; Katsuyoshi Takata; Tadashi Yoshino; Naoki Ishizuka; Masahiko Oguchi; Yukio Kobayashi; Yasushi Isobe; Kenichi Ishizawa; Nobuko Kubota; Kuniaki Itoh; Noriko Usui; Kana Miyazaki; Izumi Wasada; Shigeo Nakamura; Yoshihiro Matsuno; Kazuo Oshimi; Tomohiro Kinoshita; Kunihiro Tsukasaki; Kensei Tobinai
Journal:  Cancer Sci       Date:  2014-10-04       Impact factor: 6.716

8.  Treatment outcome of radiotherapy alone versus radiochemotherapy in IE/IIE extranodal nasal-type natural killer/T cell lymphoma: a meta-analysis.

Authors:  Tianxia Deng; Cheng Zhang; Xi Zhang; Sha Wu; Yaqi Xu; Shanshan Liu; Xinghua Chen
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

9.  Icaritin induces lytic cytotoxicity in extranodal NK/T-cell lymphoma.

Authors:  Ting Wu; Songmei Wang; Jinfeng Wu; Zhiguang Lin; Xianxian Sui; Xiaoping Xu; Norio Shimizu; Bobin Chen; Xuanyi Wang
Journal:  J Exp Clin Cancer Res       Date:  2015-02-15

10.  Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies.

Authors:  Yuan Mao; Mei Ping Lu; Hong Lin; Da Wei Zhang; Ying Liu; Qing Dong Li; Zhi Gang Lv; Jia Ren Xu; Ren Jie Chen; Jin Zhu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.